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Abstract
Context: There is no licensed oral native testosterone (NT) because of challenges in the formulation. Licensed 
oral formulations of the ester, testosterone undecanoate (TU), require a meal for absorption and generate 
supraphysiological dihydrotestosterone (DHT) levels.
Objective: To develop an oral NT formulation.
Design and methods: A lipid-based formulation of native testosterone filled into soft-gelatin capsules at 40 mg per 
capsule was designed with 2 years of stability at ambient temperature. Pharmacokinetic comparison studies of this 
oral lipidic NT formulation to oral TU were conducted in dogs and hypogonadal men.
Results: In dogs, 40 mg NT was well absorbed under fasted conditions whereas 40 mg TU required a high-fat meal: 
for NT, the mean fed/fasted AUC ratio was 1.63 and for TU 7.05. In hypogonadal men, fed and fasted NT had similar 
pharmacokinetics: Cmax mean 26.5 vs 30.4 nmol/L (769 vs 882 ng/dL), AUC0–10 h 87 vs 88.6 h nmol/L. NT (fed state) 
showed a testosterone AUC increase of 45% between 120 and 200 mg, and NT 200 mg gave a similar mean AUC0–10 h to 
TU 80 mg: 87 vs 64.8 h nmol/L. Serum TU levels were variable and on a molar basis were ~ten-fold higher than serum 
testosterone levels after TU 80 mg fed. The DHT: testosterone AUC0–10 h ratio was more physiological for NT than TU 
being 0.19 vs 0.36. There were no emerging safety concerns with NT.
Conclusion: This novel oral lipidic native testosterone formulation has potential advantages over oral TU of dosing 
independently of food and a lower risk of supraphysiological DHT levels.
Significance statement 
There is no licensed oral testosterone because of challenges in formulation, and the oral formulations of the ester, 
testosterone undecanoate, require a fatty meal for absorption and generate supraphysiological dihydrotestosterone 
levels. We have overcome the design challenges and formulated an oral native testosterone that can be taken with 
or without food and provides physiological levels of testosterone and dihydrotestosterone in hypogonadal men. This 
formulation, DITEST, has the potential advantage of being oral for patients who do not tolerate injections and less risk 
of adverse events that might theoretically be associated with elevated dihydrotestosterone levels. Future studies will 
need to define the dosing regimen for replacement in hypogonadal men.
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Introduction
Testosterone was isolated, named, and synthesized in 
1935 (1), but to date, no oral native testosterone has been 
licensed for testosterone replacement therapy. The reason 
being that oral native testosterone, although absorbed 
through the intestine, undergoes extensive pre-systemic 
metabolism along the gastrointestinal tract (2), as well 
as rapid first-pass metabolism in the liver (3). The oral 
absorption of testosterone is also dependent on the dosing 
vehicle, wherein a lipophilic vehicle may increase the 
proportion of testosterone absorbed via the lymphatic route 
(4). It is thus difficult to achieve adequate bioavailability of 
testosterone in order to maintain consistent physiological 
testosterone levels via the oral route. To address this, 
different routes of administration for testosterone have 
been used and native testosterone replacement therapy 
has been licensed as implants, transdermal, transbuccal, 
and intranasal therapies (5).
Oral 17α-alkylated androgens such as 
methyltestosterone and oxymetholone were proved 
to be effective androgen replacement therapies but 
were associated with severe liver damage including the 
development of jaundice, peliosis hepatis, and liver 
tumours (6). This toxic effect on the liver appears to be 
specific to oral modified (i.e. non-native) testosterones, 
particularly methylated testosterone and was not seen with 
native testosterone in animal models assessing liver toxicity 
(7). Testosterone undecanoate (TU) is an ester prodrug of 
testosterone and has a mid-chain length fatty acid at the 
17β position and when given orally undergoes absorption 
in part through the intestinal lymphatic pathway, so 
circumventing some of the first-pass metabolism through 
the liver (4). Oral testosterone undecanoate is presented as 
an oily capsule and has been available in Europe since the 
1970s (1); however, TU has to be taken with a meal two or three 
times daily, has an unpredictable absorption pattern, and 
generates high dihydrotestosterone (DHT) to testosterone 
ratio (8, 9, 10). An oral self-emulsifying formulation of 
TU has recently been approved in the US (Jatenzo®, Clarus 
Therapeutics Inc., USA). The formulation promotes 
solubilization and intestinal lymphatic absorption of the 
lipophilic testosterone ester. Deesterification of TU by 
nonspecific esterases in liver, blood, and tissue results in 
the production of testosterone. The liberated undecanoic 
acid moiety is metabolized via beta-oxidation. 5-Alpha 
reduction of testosterone undecanoate in the gut produces 
dihydrotestosterone undecanoate (DHTU) and DHT (11). 
The testosterone undecanoate formulation has to be taken 
with food, patients have higher than normal DHT levels 
on treatment and the label is associated with a black box 
warning regarding an increase in blood pressure (12). These 
data support the need for new developments in this area.
Various oral formulations of native testosterone have 
been tested in man although none have been licensed 
(13, 14, 15, 16, 17, 18, 19, 20). Soon after testosterone’s 
identification and characterization, oral testosterone 
administration was disregarded as a viable route of 
administration and replacement because of poor oral 
absorption (21). In the 1970s, a micronized form of 
free testosterone was demonstrated to be absorbed 
in hypogonadal men but absorption was not reliable 
enough to progress as therapy (14). Further research, 
particularly by Amory and coworkers, showed that native 
testosterone administered as a suspension in oil provided 
potentially therapeutic levels of testosterone in healthy 
men (15) and combined with 5α-reductase inhibitors 
provided physiological testosterone levels both in the 
fasted and fed state (16). Native testosterone is practically 
insoluble in water and in fatty oil vehicles (22), and the 
challenge has been to develop a solution formulation 
that contains sufficient testosterone concentration to 
provide reproducible physiological testosterone levels 
in hypogonadal men. Building upon the previous 
observations, we have developed a lipidic solution 
formulation of native testosterone and have tested it in 
dogs and humans in the fasted and fed state.
Subjects and methods
Formulation
Lipidic native testosterone (NT) formulations were 
developed and assessed in vitro for dispersion behaviour 
in gastric and intestinal media and for physical stability. 
A single formulation of NT, DITEST, was selected to take 
forward into preclinical trials (Table 1). The formulation 
used digestible lipids (oils with carbon chain length > 10 
carbons atoms) with the addition of short-medium chain 
oils and ethanol as a polar co-solvent to assist with 
solubilization. The formulation was encapsulated in size 
00 soft gelatin capsules with 40 mg per capsule inside an 
aluminium foil blister pack and was stable for 2 years at 
ambient temperature (25°C).
Pharmacokinetics in dogs
Female beagle dogs (n = 4) received a single oral 
administration on five separate occasions of either 40 mg 
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NT capsules or 40 mg TU (Andriol® Testocaps, MSD, UK) 
in the fed and fasted state or NT capsules 80 mg fed. Blood 
samples were taken at 0.5, 1, 2, 3, 4, 6, 10, 12, and 24 h 
following each dose administration.
Pharmacokinetics in hypogonadal men
A single-centre, phase 1b study to compare the 
pharmacokinetics of NT 120 and 200 mg with TU 80 mg 
(Andriol® Testocaps, MSD, UK) in adult male participants 
with primary or secondary hypogonadism (EUDRACT: 
2015-004255-46). A higher dose of NT to TU was chosen 
as NT and was expected to have reduced bioavailability 
compared to TU based on the preclinical dog studies. Key 
inclusion criteria were male aged 18–80 years; diagnosis of 
primary testicular failure or secondary hypogonadism due 
to known pituitary disease or congenital deficit; BMI > 18 
kg/m2 and <35 kg/m2; testosterone level < 8 nmol/L (232 
ng/dL) after washout of current testosterone treatment 
and normal prostate-specific antigen (PSA). Exclusion 
criteria included history of cancer, myocardial infarction, 
or unstable cardiovascular disease, and haematocrit 
levels > 0.5 L/L (50%) at baseline.
The primary objective was to compare the rate and 
extent of absorption of testosterone from a single dose of 
NT with a single dose of 80 mg TU in the fed state following 
the standard FDA high-fat, high-calorie meal defined as 
an 800–1000 calorie meal where approximately 50% of 
total caloric content comes from fat (23). The secondary 
objectives were to assess the impact of food on the rate and 
extent of absorption of testosterone from NT and the safety 
and tolerability of two different doses of NT. The exploratory 
objectives included assessing the levels of DHT in serum. 
The study was a randomized, active control, single-dose, 
two-way crossover study in two cohorts. In each cohort, 
participants were randomized to one of two treatments 
with treatments separated by a minimum 7-day washout:
Cohort 1: in the fed state with a high-fat meal either a 
single dose of 120 mg (3 × 40 mg) NT followed by a 
single dose of 80 mg (2 × 40 mg) TU or a single dose 
of 80 mg (2 × 40 mg) TU followed by a single dose of 
120 mg (3 × 40 mg) NT.
Cohort 2: a single dose of 200 mg (5 × 40 mg) NT (fed with 
a high-fat meal) followed by a single dose of 200 mg 
(5 × 40 mg) NT (fasted) or a single dose of 200 mg 
(5 × 40 mg) NT (fasted) followed by a single dose of 
200 mg (5 × 40 mg) NT (fed with a high-fat meal).
On each dosing day, samples were taken at –0.5, –0.25 
(cohort 1 only), 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 
8, and 10 h for pharmacokinetic (PK) assessment. There was 
a minimum of 3 months separation between treatments in 
cohorts 1 and 2.
Assays
Liquid chromatography with tandem mass spectrometry 
(LC-MS/MS) analysis for serum testosterone and DHT was 
performed using a Waters Xevo TQ-S TM mass spectrometer 
and a Waters AcquityTM LC system with an electrospray source 
operated in positive ionization mode. For testosterone, the 
lower limit of quantitation (LLOQ) was 0.1 nmol/L and the 
assay was linear up to 40 nmol/L. The inter-assay imprecision 
was 3.9, 3.9, and 3.1% at concentrations of 0.5, 4.7, and 14.0 
nmol/L, respectively. The reference range for adult men aged 
18–39 years is 9.2–31.8 nmol/L (24). For DHT, the LLOQ 
was 0.3 nmol/L, and the assay was linear up to 50 nmol/L. 
The inter-assay imprecision was 11.2, 8.4, and 5.8% at 
concentrations of 0.3, 0.9, and 8.3 nmol/L, respectively. The 
reference range for adult men aged < 65 is 0.8–3.5 nmol/L 
(25). LC-MS/MS analysis for serum testosterone undecanoate 
was performed using a Waters Xevo TQ-S MicroTM mass 
spectrometer and a Waters AcquityTM LC system with an 
electrospray source operated in positive ionization mode. 
For TU, the LLOQ was 0.002 nmol/L (1.0 ng/L), and the 
assay was linear up to 4.38 nmol/L (2000 ng/L). The inter-
assay imprecision was 11.2, 8.4, and 5.2% at concentrations 
of 0.02, 0.18, and 1.53 nmol/L (8.0, 80, and 700 ng/L), 
respectively. All LCMS instruments are calibrated monthly.
Statistics in hypogonadal men
PK parameters (Cmax and AUC) were calculated based 
on actual sampling times with correction for baseline 
Table 1 Oral lipidic native testosterone formulation (DITEST).
Ingredient Grade Quantity, % (w/w) Quantity per capsule (mg) Function
Testosterone Ph. Eur. 5.43 40.0 Active ingredient
Sesame oil Ph. Eur. 41.39 305.0 Carrier
Propylene glycol monolaurate Ph. Eur. 31.62 233.0 Surfactant
Benzyl alcohol Ph. Eur. 16.29 120.0 Solvent
Ethanol Ph. Eur. 5.27 38.83 Solvent
Gelatin Ph. Eur. – – Capsule shell
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testosterone that is, by subtraction of the mean of 
individual pre-dose concentrations. In each cohort, the 
primary PK endpoints were analysed using an ANOVA 
model corresponding to a two-way crossover design 
with fixed effects for sequence, treatment, period, and 
participant nested within the sequence. The comparison 
between NT 200 mg and TU 80 mg in the fed state was based 
on the ANOVA model with treatment as the only fixed 
effect. The analyses were based on the log-transformed 
concentrations. The 90% CIs for the ratio of the treatment 
effects were calculated using the mean square error from 
the ANOVA models. PK parameters (Cmax and AUC) from 
the non-compartmental analysis were cross-correlated 
with body weight.
Ethics
The study protocol was approved by the North West – 
Greater Manchester South Research Ethics Committee 
(Reference number: 16/NW/0242: 193020) and the 
Medicines and Healthcare Products Regulatory Agency 
(MHRA), UK. The trial was performed in accordance 
with the ethical principles that have their origins in the 
Declaration of Helsinki (October 2013) and in accordance 
with International Conference for Harmonisation Good 




Baseline corrected quantifiable testosterone concentrations 
were reported in all animals (n = 4) on all dosing occasions 
up to at least 4 h after dosing with NT and TU. For NT, 
systemic exposure of testosterone approximately doubled 
following an increase in the administered dose from 40 to 
80 mg fed, suggesting dose proportionality. TU was poorly 
absorbed when fasted: geometric mean AUC h ng/mL 
fasted vs fed 10.7 vs 64.6 whereas NT was absorbed fasted 
with less difference between geometric mean AUC fasted vs 
fed 15.4 h ng/mL vs 25.5 h ng/mL (Table 2). The ratio (90% 
CI) fed: fasted for AUC was 1.63 (1.19–2.07) for NT vs 7.05 
(5.79–8.31) for TU.
Demographics of hypogonadal men
A total of 30 participants were screened, with 8 participants 
failing screening and not taking part in the study (Fig. 1). 
The reasons for screen failure were testosterone 
level > 8 nmol/L (232 ng/dL) (n = 5), haematocrit > 0.5 
(n = 1), BMI > 35 kg/m2 (n = 1) and unable to consume the 
standard high-fat breakfast (n = 1). A total of 22 participants 
were enrolled in the study (in either cohort 1, cohort 2, or 
both cohorts) and received at least one study intervention. 
Three participants were enrolled in both cohorts since 
participants from cohort 1 could be entered into cohort 2 
after a washout period of at least 3 months between cohorts. 
For the purposes of the analysis, these three participants 
were handled as separate participants in each cohort so a 
total of 25 individual cases were randomized and treated 
during the study (Fig. 1). In the overall safety set (n = 25), 
participants had a mean (s.d.): age of 53.8 (13.9) years; 
body weight of 91.7 (13.0) kg; BMI of 29.1 (3.7) kg/m2. Most 
participants were white (92.0%). Mean ± s.d. baseline 
serum testosterone was 3 ± 2.6 nmol/L (87 ± 75 ng/dL) 
(Table 3). One participant in cohort 1 was withdrawn early 
from the study because he started a prohibited medication 
during the washout between treatment periods. This 
participant only received the study intervention in period 
1 (TU) and was replaced. Twelve participants completed 
the study in each cohort.
Pharmacokinetics in hypogonadal men
Cohort 1, comparing 120 mg NT with 80 mg TU taken in the 
fed state with a high-fat meal showed both formulations 
generated testosterone levels in the physiological range and 
80 mg TU gave higher testosterone levels than 120 mg NT 
(Fig. 2). NT had an earlier Tmax than TU: 1.4 vs 4.2 h (Table 
4). NT resulted in around 50% lower levels of DHT than TU, 
Table 2 Pharmacokinetic parameters for NT and TU in dogs.
Formulation Testosterone dose (mg) Fasted or fed Tmax(obs) (h)* Cmax(obs) (ng/mL)
† AUC0-t (h ng/mL)
†
NT 40 Fasted 0.50 (0.50, 1.00) 7.98 (32.9) 15.4 (16.6)
NT 40 Fed 0.50 (0.50, 0.50) 11.0 (35.3) 25.5 (26.8)
NT 80 Fed 1.00 (1.00, 3.00) 18.7 (38.1) 63.3 (20.6)
TU 40 Fasted 1.50 (1.00, 10.0) 1.78 (45.3) 10.7 (25.4)
TU 40 Fed 2.00 (1.00, 10.0) 18.0 (83.8) 64.6 (20.0)
*Values are median (range); †Values are geometric mean (CV%).
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Cohort 1 Cohort 2
Overall (n = 25)Sequence 1 (n = 6) Sequence 2 (n = 7) All (n = 13) Sequence 1 (n = 6) Sequence 2 (n = 6) All (n = 12)
Age, years
 Mean (s.d.) 45.8 (9.2) 57.3 (18.7) 52 (15.7) 58.2 (15.7) 53.3 (7.5) 55.8 (12.0) 53.8 (13.9)
 Min-Max 34–60 35–78 34–78 36–72 44–61 36–72 34–78
Height, m
 Mean (s.d.) 1.81 (0.04) 1.76 (0.05) 1.79 (0.05) 1.75 (0.04) 1.77 (0.04) 1.76 (0.04) 1.77 (0.05)
 Min-Max 1.75–1.88 1.68–1.81 1.68–1.88 1.72–1.82 1.70–1.82 1.70–1.82 1.68–1.88
Weight, kg
 Mean (s.d.) 93.82 (18.73) 87.19 (10.68) 90.25 (14.66) 96.00 (13.42) 90.72 (9.57) 93.36 (11.45) 91.74 (13.04)
 Min-Max 70.00–126.00 77.00–108.60 70.00–126.00 73.00–108.80 81.00–106.44 73.00–108.80 70.00–126.00
BMI, kg/m2
 Mean (s.d.) 28.36 (4.66) 28.10 (3.54) 28.22 (3.92) 31.36 (3.84) 28.82 (2.42) 30.09 (3.33) 29.11 (3.70)
 Min-Max 21.85–35.65 23.50–33.15 21.85–35.65 24.39–34.74 25.51–32.49 24.39–34.74 21.85–35.65
Cohort 1, Sequence 1: 120 mg NT followed by a single dose of 80 mg TU; Cohort 1, Sequence 2: 80 mg TU followed by 120 mg NT; Cohort 2, Sequence 1: 200 mg NT in the fed state followed by 200 
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The preclinical study in dogs showed that the oral lipidic 
NT formulation showed less variability in absorption 
between the fasted and fed state compared to TU and that 
very little TU was absorbed in the fasted state, confirming 
previous results in the literature (26). The results for the NT 
formulation were confirmed in hypogonadal men where 
the NT formulation showed similar pharmacokinetics 
when taken fasted or fed and the ratio of DHT to testosterone 
was lower for NT than TU.
It is known that native testosterone is absorbed 
orally but because of the extensive pre-systemic 
metabolism in the gastrointestinal tract and rapid first-
pass metabolism in the liver, a high dose is required to 
replace physiological circulating serum testosterone levels 
(1). This is compounded by the fact that testosterone is 
practically insoluble in water and fatty acid oils (22), so it 
has been challenging to generate a solution formulation of 
testosterone with a testosterone concentration sufficient to 
replace circulating testosterone levels. We have addressed 
this by generating a lipidic solution formulation where 
testosterone is held in solution in the oil phase through 
the addition of co-solvents: ethanol and benzyl alcohol. 
The formulation is stable at room temperature for up to 2 
years and provides reproducible physiological testosterone 
levels in hypogonadal men.
TU, an ester prodrug of testosterone, given orally, 
undergoes absorption through the intestinal lymphatic 
pathway and thus circumvents first-pass metabolism 
through the liver. The Tmax for NT was earlier than TU 
in both the dog and hypogonadal men reflecting that 
the NT formulation is likely primarily absorbed via the 
intestinal transcellular route through the hepatic portal 
circulation. In the fed state, TU provided higher levels 
of circulating testosterone per unit dose of testosterone 
than NT; however, the TU levels of the prodrug in the 
circulation were ~ten-fold greater than serum testosterone 
levels on a molar basis and showed great variation. This 
result is similar to the ~ten-fold greater levels of TU 
prodrug than total testosterone previously reported for 
TU (11), suggesting that, although TU is well absorbed, a 
relatively low fraction is converted to testosterone and 
most of that conversion probably takes place in the gut at 
the time of absorption as does the generation of DHT. The 
FDA-approved TU formulation, Jatenzo®, recommends a 
starting dose of 237 mg (150 mg of unesterified testosterone 
equivalents based on molecular weight) and a maximum 
dose of 396 mg (250 mg testosterone equivalents) twice 
daily (12). These are similar to the dosing levels of the NT 
formulation used in the phase 1b study, 120 to 200 mg, 
that provided a physiological testosterone concentration. 
The recommended starting dose of the European approved 
TU formulation, Andriol®, is 120–160 mg (75–100 mg 
testosterone) daily and in our study, we found higher 
testosterone levels after 80 mg Andriol® taken with a high-
fat meal than after NT 120 mg. The difference in apparent 
bioavailability of the different TU formulations may relate 
to the fat content of the meal in studies or the formulation.
TU requires a fat-containing meal for absorption (8, 9, 
10), as illustrated here by very low circulating testosterone 
Figure 2
Mean (s.e.m.) serum testosterone and DHT levels following NT 
120 mg and TU 80 mg.
Figure 3
Mean (s.e.m.) serum TU and testosterone levels after TU  
80 mg fed.
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levels in the dogs when TU was given fasted. Currently, there 
is only one marketed US Food and Drug Administration 
(FDA)-approved TU oral product, Jatenzo®, with potentially 
a second product available shortly, Tlando (Lipocine Inc., 
US), which has reported conditional approval from the 
FDA. Jatenzo® was poorly absorbed fasted, TU and DHTU 
concentrations were 6.2- and 8.8-fold higher, respectively, 
in the fed state (30% fat meal) compared with fasting (11), 
and in the phase 3 study was administered twice daily with 
food (12). In contrast, we have demonstrated that native 
non-esterified testosterone absorption is not affected 
by food.
TU formulations that replace physiological testosterone 
levels generate supraphysiological levels of DHT (13), 
whereas NT formulations provide more physiological 
levels of DHT (20). The lipidic NT formulation reported 
here generated a more physiological ratio of DHT to total 
testosterone compared to TU. To date, there is no evidence 
that raised DHT levels are harmful, although theoretically 
there may be more impact on DHT responsive tissues such 
as skin and prostate. Reassuringly, however, the increased 
serum DHT concentrations resulting from therapy with 
oral testosterone undecanoate were not associated with an 
increased risk of prostate cancer or prostate enlargement 
in long-term studies (27). The impact of 17α-alkylated 
androgens on liver toxicity has not been seen with NT 
formulations (20), and no change in liver function tests 
was seen in this single-dose study with the NT formulation. 
However, longer-term studies with NT are required to 
examine the impact on liver function. After NT dosing, 
there was a negative correlation between PK parameters 
suggesting that the greater the weight the lower the Cmax 
and AUC, but the correlation was weak and testosterone 
replacement is generally titrated according to serum 
testosterone levels in the individual rather than weight.
This manuscript reports clinical data from a single-
dose study in a cohort of hypogonadal men, and future 
studies will need to generate 24-h pharmacokinetic data 
at a steady state for a range of dose levels. Consideration 
will also need to be given to increasing the dose per 
capsule, measuring SHBG levels, and investigating the 
potential need for dose titration in clinical practice. 
Testosterone may induce its own metabolism and so the 
impact of repeat dosing will need to be examined (14). 
Table 4 Pharmacokinetic summary of data comparing native testosterone (NT) with testosterone undecanoate (TU) and NT 
taken fasted and fed in hypogonadal men (baseline-adjusted pharmacokinetic set). Data are presented as mean (s.d.).
Cohort 1† Cohort 2‡
DITEST 120 mg TU 80 mg  GLSM ratio (90% CI) Fed Fasted  GLSM ratio (90% CI)
Testosterone
 Cmax
  ng/dL 554 (481) 911 (670) 55.6 (45–68.7) 769 (421) 882 (458) 85.1 (57.5–126.0)
  nmol/L 19.1 (16.6) 31.4 (23.1) 26.5 (14.5) 30.4 (15.8)
 AUC0–10 h
  h ng/dL 1726 (1578) 2958 (2480) 51.3 (34.7–75.7) 2523 (1615) 2569 (1496) 94.2 (66.1–134.2)
  h nmol/L 59.5 (54.4) 102 (85.5) 87.0 (55.7) 88.6 (51.6)
 Tmax h 1.4 (1.0) 4.2 (2.1) 1.4 (0.6) 1.2 (0.6)
TU
 Cmax
  ng/dL 20 900 (8500)
  nmol/L 458 (186)
 AUC0–10 h
  h ng/dL 47 200 (18500)




  ng/dL 84 (99) 194 (119) 119 (58) 131 (61)
  nmol/L 2.9 (3.4) 6.7 (4.1) 4.1 (2.0) 4.5 (2.1)
 AUC0–10 h
  h ng/dL 319 (351) 1053 (850) 467 (270) 484 (299)
  h nmol/L 11.0 (12.1) 36.3 (29.3) 16.1 (9.3) 16.7 (10.3)
 Tmax h 2.4 (2.1) 5.7 (1.9) 1.7 (0.6) 1.6 (0.7)
To convert testosterone nmol/L to ng/dL multiply by 29; To convert DHT nmol/L to ng/dL multiply by 29; To convert TU ug/L to ng/dL multiply by 100; To 
convert TU multiply ug/L by 2.19 to get nmol/L. †Fed NT 120 mg vs TU 80 mg. ‡NT 200 mg fed vs fasted.
GLSM, geometric least squared mean.
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The levels of testosterone, DHT, and TU were quantified 
from serum samples, and following the start of the study 
in hypogonadal males it was recognized that TU can be 
converted to testosterone in serum ex vivo and, therefore, 
the testosterone levels measured after TU administration 
may be higher than they would have been if measured in 
plasma (28).
In conclusion, we have developed a lipidic NT 
formulation, which when given to hypogonadal men 
generates similar testosterone and DHT exposure in the 
fed and fasted state. Compared to published literature on 
a self-emulsifying formulation of TU at 200 mg (12), the 
NT formulation at 200 mg provides a similar testosterone 
Cmax and no requirement for a meal. This oral lipidic native 
testosterone formulation has anticipated advantages over 
current oral therapy of dosing with or without food and a 
lower risk of supraphysiological DHT levels.
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